Hackensack, New Jersey Clinical Trials

A listing of Hackensack, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 193 clinical trials
A Study of AK104 a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

cancer treatment
metastatic cervical carcinoma
adenosquamous carcinoma
cervical carcinoma
immunosuppressive
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
 (10.0 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +19 other locations
Double-Blind Multicenter Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

This clinical trial will examine if a new treatment of Mesenchymal Stems Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.

covid-19
acute respiratory distress
respiratory distress
SARS
acute respiratory syndrome (sars)
Holy Medical Center
 (2.0 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +2 other locations
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS.

myeloid leukemia
glomerular filtration rate
remission
hematologic malignancy
cervical cap
Memorial Sloan Kettering Cancer Center
 (9.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +4 other locations
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see …

chronic lymphocytic leukemia
venetoclax
remission
antibody therapy
lymphoid leukemia
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
THE ALIGN-AR PIVOTAL TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may …

shortness of breath
fatigue
regurgitation
aortic valve replacement
New York-Presbyterian/ Columbia University Medical Center
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study …

hydroxychloroquine
serologic test
prostate cancer
anosmia
antigen test
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
 (9.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

daratumumab
multiple myeloma
autologous hematopoietic stem cell transplant
immunotherapeutic agent
ixazomib
Investigational Site Number 8400001
 (8.6 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +7 other locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

James J. Peters VA Medical Center
 (8.1 away)
  • 0 views
  • 14 Mar, 2022
  • +1 other locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI test  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Accepts healthy volunteers
James J. Peters VA Medical Center
 (8.1 away)
  • 0 views
  • 14 Mar, 2022
  • +1 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

genetic testing
alpha-synuclein
resting tremor
datscan
tremor
Columbia University Medical Center
 (6.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +45 other locations